Faculty and Writing Committee, American Association for Respiratory Care Consensus Conference on Aerosol Delivery. Aerosol Consensus Statement-1991. Respir Care1991;36:916–921.
2.
GuglielmoBJ, JacobsRA, LocksleyRM. The exposure of health care workers to ribavirin aerosol (letter). JAMA1989;261:1880–1881.
3.
Assessing exposures of health-care personnel to aerosols of ribavirin-California. MMWR1988;37(36):560–563.
SmithDW, FrankelLR, MathersLH, TangAT, AriagnoRL, ProberCG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med1991;325:224–229.
6.
SungR, et al. Ribavirin treatment of severe respiratory syncytial viral infection in infants and young children-a local experience. J Hong Kong Med Assoc1990;42:80–82.
HallCB, McBrideJT, WalshEE, BellDM, GalaCL, HildrethS, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. N Engl J Med1983;308:1443–1447.
9.
HallC, McBrideJT, GalaCL, HildrethSW, SchnabelKC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA1985;254:3047–3051.
10.
RodriguezW, KimH, BrandtCD, FinkRJ, GetsonPR, ArrobioJ, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J1987;6:159–163.
11.
TaberL, KnightV, GilbertBE, McClungHW, WilsonSZ, NortonHJ, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics1983;72:613–618.
12.
GroothuisJ, WoodinK, KatzR, RobertsonAD, McBrideJT, HallCB, et al. Early ribavirin treatment of respiratory syncytial virus infection in high-risk children. J Pediatr1990;5:792–798.
13.
RobertsR, DickinsonGM, HeseltinePN, LeedomJM, AnsellPW, RodriguezWJ, et al. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. J Acquir Immune Defic Syndr1990;3:884–892.
14.
Viratek. Data on File. Costa Mesa CA.
15.
RodriguezWJ, BuiRH, ConnorJD, KimHW, BrandtCD, ParrottRH, et al. Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrob Agents Chemother1987;31:1143–1146.
16.
HarrisonR.Reproductive risk assessment with occupational exposure to ribavirin aerosol. Pediatr Infect Disease J1990;9(Suppl):S102–S105.
17.
EnglundJ, PiedraPA, JeffersonLS, WilsonSZ, TaberLH, GilbertBE. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr1990;117:313–320.
18.
TorresAJr, KrilovLR, JacobsonJM, KellyKN, HavensPL. Reduced environmental exposure to aerosolized ribavirin using a simple containment system. Pediatr Infect Dis J1991;10:217–221.
19.
KorenG.Studying the safety of ribavirin in human pregnancy. Pediatr Infect Dis J1990;9(Suppl):S106–S107.
20.
Report of the Committee on Infectious Diseases, The American Academy of Pediatrics, 1991, 22nd ed:581–587.
21.
Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Ribavirin: is there a risk to hospital personnel?Can Med Assoc J1991;144:285–286.
22.
Ribavirin and respiratory syncytial virus (editorial). Lancet1986;1(8477):362–363.
